FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2306030387> ?p ?o ?g. }

• W2306030387 endingPage "149" @default.
• W2306030387 startingPage "143" @default.
• W2306030387 abstract "The results of controlled clinical trial that used high doses of medroxyprogesterone acetate (MPA) in the treatment of metastatic breast cancer are reported. Two treatment reigmens were used: regimen A, 500 mg daily with a total dose of 30 g; regimen B, 1,000 mg daily with a total dose of 60 g. The overall response rates were similar, with no statistically significant difference between the two treated groups. Regimen A (lower dosage group) reached a remission rate of 44%, whereas regimen B (higher dosage group) had a remission rate of 41%. The mean duration of response was 8 months with regimen A and 9 months with regimen B. The advantages of the lower dosage regimen as opposed to the higher dosage regimen of MPA in the treatment of advanced breast cancer are discussed.A controlled clinical trial that used high doses of medroxyprogesterone acetate (MPA) in the treatment of metastatic breast cancer was conducted. Therapy consisted of 2 treatments: regimen A, 500 mg daily with a total dose of 30 g; regimen B, 1000 mg daily with a total dose of 60 g. From June 1975 to September 1976, 101 patients entered into the study and were randomly allocated into the 2 treatment groups. Both treatment groups were comparable in terms of age, menopausal status, free interval, and dominant site of lesions. Selection of patients was done according to the following criteria: histologically proved progressive metastatic carcinoma of the breast, without any treatment for at least 2 months; no prior hormonal manipulation; performance status 50 or more, and life expectancy longer than 3 months; measurable disease. Overall response rates were similar, with no statistically significant difference between the 2 treated groups. Regimen A reached a remission rate of 44%; regimen B had a remission rate of 41%. The mean duration of response was 8 months with regimen A and 9 months with regimen B. Both regimens were well tolerated. Clinical toxicity was mild with both dosages of MPA. The main side effect was gluteus abscess, with a higher incidence in group B. This was probably due to the greater amount of injected drug suspension in the 1000 mg/day regimen. The incidence of thrombophlebitis and vaginal bleeding was negligible." @default.
• W2306030387 created "2016-06-24" @default.
• W2306030387 creator A5013536853 @default.
• W2306030387 creator A5024403801 @default.
• W2306030387 creator A5038101218 @default.
• W2306030387 creator A5066900859 @default.
• W2306030387 creator A5085919452 @default.
• W2306030387 date "1978-04-01" @default.
• W2306030387 modified "2023-09-27" @default.
• W2306030387 title "High Dose Medroxyprogesterone Acetate (MPA) Treatment in Metastatic Carcinoma of the Breast: A Dose-Response Evaluation" @default.
• W2306030387 cites W2046850438 @default.
• W2306030387 cites W2075768688 @default.
• W2306030387 cites W2406806768 @default.
• W2306030387 cites W2417813231 @default.
• W2306030387 doi "https://doi.org/10.1177/030089167806400204" @default.
• W2306030387 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/354147" @default.
• W2306030387 hasPublicationYear "1978" @default.
• W2306030387 type Work @default.
• W2306030387 sameAs 2306030387 @default.
• W2306030387 citedByCount "67" @default.
• W2306030387 countsByYear W23060303872013 @default.
• W2306030387 countsByYear W23060303872014 @default.
• W2306030387 crossrefType "journal-article" @default.
• W2306030387 hasAuthorship W2306030387A5013536853 @default.
• W2306030387 hasAuthorship W2306030387A5024403801 @default.
• W2306030387 hasAuthorship W2306030387A5038101218 @default.
• W2306030387 hasAuthorship W2306030387A5066900859 @default.
• W2306030387 hasAuthorship W2306030387A5085919452 @default.
• W2306030387 hasConcept C121608353 @default.
• W2306030387 hasConcept C126322002 @default.
• W2306030387 hasConcept C126894567 @default.
• W2306030387 hasConcept C141071460 @default.
• W2306030387 hasConcept C2775930923 @default.
• W2306030387 hasConcept C2775934596 @default.
• W2306030387 hasConcept C2776306185 @default.
• W2306030387 hasConcept C2781413609 @default.
• W2306030387 hasConcept C530470458 @default.
• W2306030387 hasConcept C71315377 @default.
• W2306030387 hasConcept C71924100 @default.
• W2306030387 hasConceptScore W2306030387C121608353 @default.
• W2306030387 hasConceptScore W2306030387C126322002 @default.
• W2306030387 hasConceptScore W2306030387C126894567 @default.
• W2306030387 hasConceptScore W2306030387C141071460 @default.
• W2306030387 hasConceptScore W2306030387C2775930923 @default.
• W2306030387 hasConceptScore W2306030387C2775934596 @default.
• W2306030387 hasConceptScore W2306030387C2776306185 @default.
• W2306030387 hasConceptScore W2306030387C2781413609 @default.
• W2306030387 hasConceptScore W2306030387C530470458 @default.
• W2306030387 hasConceptScore W2306030387C71315377 @default.
• W2306030387 hasConceptScore W2306030387C71924100 @default.
• W2306030387 hasIssue "2" @default.
• W2306030387 hasLocation W23060303871 @default.
• W2306030387 hasLocation W23060303872 @default.
• W2306030387 hasOpenAccess W2306030387 @default.
• W2306030387 hasPrimaryLocation W23060303871 @default.
• W2306030387 hasRelatedWork W1969181770 @default.
• W2306030387 hasRelatedWork W1977264199 @default.
• W2306030387 hasRelatedWork W1989201687 @default.
• W2306030387 hasRelatedWork W1990549387 @default.
• W2306030387 hasRelatedWork W1993189381 @default.
• W2306030387 hasRelatedWork W2113695553 @default.
• W2306030387 hasRelatedWork W2275054999 @default.
• W2306030387 hasRelatedWork W2306030387 @default.
• W2306030387 hasRelatedWork W2516704757 @default.
• W2306030387 hasRelatedWork W4298925587 @default.
• W2306030387 hasVolume "64" @default.
• W2306030387 isParatext "false" @default.
• W2306030387 isRetracted "false" @default.
• W2306030387 magId "2306030387" @default.
• W2306030387 workType "article" @default.